Floatz logo

Encorafenib

Skin Carcinoma

H. Lee Moffitt Cancer Center and Research InstituteSmall moleculeEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

39 Active assets in the Skin Carcinoma cohort.

Asset / SponsorPhaseRating
1-235-TUMOR NECROSIS FACTOR RECEPTOR (HUMAN) FUSION PROTEIN WITH 236-467-IMMUNOGLOBULIN G1 (HUMAN .GAMMA.1-CHAIN FC FRAGMENT), DIMER
University of Alabama at Birmingham
Phase 4BB
Pembrolizumab
Essen Biotech
Phase 2BB
Multiple Vitamins Injection
Women's College Hospital
Phase 3BB
gsk1120212
Cancer Research UK
Phase 2/3B
Dabrafenib
Cancer Research UK
Phase 2/3B

View all 50 →

Same molecule, other indications

Encorafenib is also rated in:

colon carcinomaDormant
BB
Indicative ·
68 / 100
View asset →
colon adenocarcinomaDormant
BB
Indicative ·
67 / 100
View asset →
colorectal cancerDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →